Humpath.com - Human pathology

Home > A. Molecular pathology > TCL1A

TCL1A

MIM.186960 14q32.1 HGNC:11648 Entrez:8115

Wednesday 15 October 2008

The assembly of a collection of gene-expression signatures of the major types of B-cell non-Hodgkin’s lymphoma has identified increased T-cell leukemia/lymphoma 1A (TCL1) expression in multiple lymphoma types and cases, and has enabled the investigation of the functional and clinical importance of TCL1 expression.

Specifically, Burkitt’s lymphoma cases show a homogeneously strong expression of TCL1, whereas diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, chronic lymphocytic leukemia, nodal marginal zone lymphoma, and splenic marginal zone lymphoma display a striking variability in the intensity of TCL1 staining.

TCL1 expression is correlated with shorter time to treatment in chronic lymphocytic leukemia cases and shorter lymphoma-specific survival in mantle cell lymphoma series, thus indicating the clinical and biological significance of TCL1 expression, and suggesting TCL1A as a potential therapeutic target (18820675).

See also

- TCK1

References

- Diagnostic Utility of Novel Stem Cell Markers SALL4, OCT4, NANOG, SOX2, UTF1, and TCL1 in Primary Mediastinal Germ Cell Tumors. Liu A, Cheng L, Du J, Peng Y, Allan RW, Wei L, Li J, Cao D. Am J Surg Pathol. 2010 May;34(5):697-706. PMID: 20410807

- Aggarwal M, Villuendas R, Gomez G, Rodriguez-Pinilla SM, Sanchez-Beato M, Alvarez D, Martinez N, Rodriguez A, Castillo ME, Camacho FI, Montes-Moreno S, Garcia-Marco JA, Kimby E, Pisano DG, Piris MA. TCL1A expression delineates biological and clinical variability in B-cell lymphoma. Mod Pathol. 2008 Sep 26. PMID: 18820675